Intersubtype differences in the effect of a rare p24 Gag mutation on HIV-1 replicative fitness
- Denis R. Chopera ,
- Laura A. Cotton ,
- Alexander Zawaira ,
- Jaclyn K. Mann ,
- Nobubelo K. Ngandu ,
- Roman Ntale ,
- Jonathan M. Carlson ,
- Koleka Mlisana ,
- Zenda Woodman ,
- Debra de Assis Rosa ,
- Eric Martin ,
- Toshiyuki Miura ,
- Florencia Pereyra ,
- Bruce D. Walker ,
- Clive M. Gray ,
- Darren P. Martin ,
- Thumbi Ndung'u ,
- Mark A. Brockman ,
- Salim Abdool Karim ,
- Zabrina L. Brumme ,
- Carolyn Williamson
Journal of Virology |
Certain immune-driven mutations in HIV-1, such as those arising in p24Gag, decrease viral replicative capacity. However, inter-subtype differences in the replicative consequences of such mutations have not been explored. In HIV-1 subtype B, the p24Gag M250I mutation is a rare variant (0.6%) that is enriched among elite controllers (7.2%) (p=0.0005) and appears to be a rare escape variant selected by HLA-B58 supertype alleles (p<0.01). By contrast, in subtype C, it is a relatively common minor polymorphic variant (10-15%) whose appearance is not associated with a particular HLA allele. Using site-directed mutant viruses, we demonstrate that M250I reduces in vitro viral replicative capacity in both subtype B and subtype C sequences. However, whereas in subtype C downstream compensatory mutations at p24Gag codons 252 and 260 reduce the adverse effects of M250I, fitness costs in subtype B appear difficult to restore. Indeed, patient-derived subtype B sequences harboring M250I exhibited in vitro replicative defects while those from subtype C did not. The structural implications of M250I were predicted by protein modeling to be greater in subtype B versus C, providing a potential explanation for its lower frequency and enhanced replicative defects in subtype B. In addition to accounting for genetic differences between HIV-1 subtypes, the design of CTL-based vaccines may need to account for differential effects of host-driven viral evolution on viral fitness.